Provided by Tiger Trade Technology Pte. Ltd.

iShares Health Innovation Active ETF

33.65
-0.3282-0.97%
Post-market: 33.650.00000.00%16:10 EDT
Volume:3K
Turnover:102.82K
Market Cap:13.46M
PE:- -
High:33.77
Open:33.77
Low:33.14
Close:33.98
52wk High:34.98
52wk Low:27.25
Shares:400.00K
Float Shares:400.00K
Volume Ratio:1.96
T/O Rate:0.77%
Dividend:0.08
Dividend Rate:0.24%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Nurix - to Receive $10 Mln Research Term Extension Fee

THOMSON REUTERS
·
Oct 05

Nurix - Retains Co-Development and 50/50 Profit Sharing Options on Two U.S. Programs

THOMSON REUTERS
·
Oct 05

Edwards Lifesciences to Host Investor Event Alongside TCT Symposium Webcast

Reuters
·
Oct 05

Gene Editing, Protein Electron Transfer, Self-Assembled Monolayers 鈥?Which Will Win the Nobel Prize in Chemistry? Two Experts Share Their Predictions

Deep News
·
Oct 04

Edwards Lifesciences (EW) Receives a Buy from RBC Capital

TIPRANKS
·
Oct 03

Perrigo Co. PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 03

Biogen Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Oct 03

Gilead CEO Daniel O’Day Disposes of USD 2,216,507.50 in Common Shares

Reuters
·
Oct 03

Gilead Sciences Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Oct 03

Why Medtronic's $4 Billion MiniMed Exchange Offer is Losing Its Allure

Dow Jones
·
Oct 03

Biogen Says Litifilimab Safety Profile Consistent with no New Safety Signals Identified

Reuters
·
Oct 03

Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says

MT Newswires Live
·
Oct 03

Biogen's Experimental Lupus Drug Shows Benefit Against Skin Symptoms

Reuters
·
Oct 03

Biogen’s Salanersen Trial Strengthens Its SMA Pipeline Outlook

TIPRANKS
·
Oct 03

Biogen Says Litifilimab Posts Sustained Skin Clearance in 52-Week Phase 2 Cutaneous Lupus Study

Reuters
·
Oct 02

Biogen - 28.8% of Participants Achieve 70% or Greater Reduction in Clasi a at Week 52

THOMSON REUTERS
·
Oct 02

Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 Amethyst Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus~

THOMSON REUTERS
·
Oct 02

Biogen - Serious Adverse Events Occurred in 3.4% of Participants During 52-Week Treatment Period

THOMSON REUTERS
·
Oct 02

Biogen - 33.7% of Crossover Participants Report Clear or Almost Clear Skin at Week 52

THOMSON REUTERS
·
Oct 02

Johnson & Johnson announces two-year data from Phase 3 ICONIC-TOTAL study

TIPRANKS
·
Oct 02